切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2024, Vol. 13 ›› Issue (05) : 273 -278. doi: 10.3877/cma.j.issn.2095-3216.2024.05.006

综述

慢性肾脏病患者并发心血管疾病相关生物标志物研究进展
冯熔熔1, 苏晓乐1, 王利华1,()   
  1. 1.030001 太原,山西医科大学第二医院肾内科
  • 收稿日期:2024-01-15 出版日期:2024-10-28
  • 通信作者: 王利华

Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease

Rongrong Feng1, Xiaole Su1, Lihua Wang1,()   

  1. 1.Department of Nephrology,Second Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China
  • Received:2024-01-15 Published:2024-10-28
  • Corresponding author: Lihua Wang
引用本文:

冯熔熔, 苏晓乐, 王利华. 慢性肾脏病患者并发心血管疾病相关生物标志物研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 273-278.

Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.

心血管疾病(CVD)是慢性肾脏病(CKD)患者的常见并发症,也是导致其死亡的主要原因。 对于具有CVD 风险的CKD 患者进行早期识别和干预,有助于降低CVD 并发症发病率和CKD 患者死亡率。 本文综述了CKD 患者CVD 并发症相关新型生物标志物(肾功能相关标志物、循环系统标志物和肠源性毒素等)的研究进展。

Cardiovascular disease (CVD) is a common complication and leading cause of death in patients with chronic kidney disease (CKD). Early identification and intervention of CKD patients at risk for CVD can help reduce the incidence of CVD complications and mortality of CKD patients. This article reviewed the research progress of novel biomarkers related to complication of CVD in patients with CKD,such as renal function-related markers,circulatory system markers,and enterotoxin-derived toxins.

表1 肾功能相关标志物促心血管疾病发生发展机制
表2 循环系统标志物促心血管疾病发生发展机制
表3 肠源性毒素促心血管疾病发生发展机制
[1]
Francis A,Harhay MN,Ong ACM,et al. Chronic kidney disease and the global public health agenda: an international consensus [J]. Nat Rev Nephrol,2024,20(7):473-485.
[2]
Zoccali C,Mark PB,Sarafidis P,et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease[J]. Nat Rev Nephrol,2023,19(11):733-746.
[3]
Matsushita K,Ballew SH,Wang AY,et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease [J]. Nat Rev Nephrol,2022,18(11):696-707.
[4]
Quiroga B,Díez J. Estimation of glomerular filtration rate in cardiorenal patients: a step forward [J]. Clin Kidney J,2023,16(7):1049-1055.
[5]
Huerta A,López B,Ravassa S,et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism [J]. J Hypertens,2016,34(1):130-138.
[6]
Shen Y,Zhang X,Li C,et al. Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy [J]. Ann Transl Med,2020,8(22):1514.
[7]
Jung E,Ro YS,Ryu HH,et al. Cystatin C and mortality risk in the general population: systematic review and dose response meta-analysis [J]. Biomarkers,2022,27(3):222-229.
[8]
Lv Z,Fu Y,Liu C,et al. The role of cardiac remodeling associated with renal function in mediating cardiovascular event outcomes [J]. iScience,2024,27(3):109143.
[9]
Mizdrak M,Kumric M,Kurir TT,et al. Emerging biomarkers for early detection of chronic kidney disease [J]. J Pers Med,2022,12(4):548.
[10]
Yang HH,Wang X,Li S,et al. Lipocalin family proteins and their diverse roles in cardiovascular disease [J]. Pharmacol Ther,2023,244:108385.
[11]
Gu Y,Sun W,Xu ZH,et al. Neutrophil gelatinase-associated lipocalin 2 accelerates hypoxia-induced endothelial cell injury via eNOS/NRF2 signalling [J]. Cell J,2021,23(4):435-444.
[12]
Hasegawa M,Ishii J,Kitagawa F,et al. Plasma neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease [J]. Biomed Res Int,2016,2016:8761475.
[13]
Song X,Cai D,Zhang B. Clinical values of serum NGAL combined with NT-proBNP in the early prognosis of type 1 cardiorenal syndrome [J]. Am J Transl Res,2021,13(4):3363-3368.
[14]
Kim IY,Kim JH,Kim MJ,et al. Plasma neutrophil gelatinaseassociated lipocalin is independently associated with left ventricular hypertrophy and diastolic dysfunction in patients with chronic kidney disease [J]. PLoS One,2018,13(10):e0205848.
[15]
Wybraniec MT,Chudek J,Mizia-Stec K. Association between elevated urinary levels of kidney injury molecule type 1 and adverse cardiovascular events at 12 months in patients with coronary artery disease [J]. Pol Arch Intern Med,2018,128(5):301-309.
[16]
Feldreich T,Nowak C,Fall T,et al. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease[J]. J Nephrol,2019,32(1):111-119.
[17]
Park M,Hsu CY,Go AS,et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death:the CRIC study [J]. Clin J Am Soc Nephrol,2017,12(5):761-771.
[18]
McMillan R,Skiadopoulos L,Hoppensteadt D,et al. Biomarkers of endothelial,renal,and platelet dysfunction in stage 5 chronic kidney disease hemodialysis patients with heart failure [J]. Clin Appl Thromb Hemost,2018,24(2):235-240.
[19]
Kaplan P,Tatarkova Z,Sivonova MK,et al. Homocysteine and mitochondria in cardiovascular and cerebrovascular systems [J].Int J Mol Sci,2020,21(20):7698.
[20]
Spence JD,Urquhart BL. Cerebrovascular disease,cardiovascular disease,and chronic kidney disease:interplays and influences [J].Curr Neurol Neurosci Rep,2022,22(11):757-766.
[21]
Ding C,Li J,Wei Y,et al. Associations of total homocysteine and kidney function with all-cause and cause-specific mortality in hypertensive patients: a mediation and joint analysis [J].Hypertens Res,2024,47(6):1500-1511.
[22]
ALSolami AA,Almalki AA,Alhedyan SY,et al. Plasma homocysteine levels and cardiovascular events in patients with end-stage renal disease: a systematic review [J]. Cureus,2023,15(6): e40357.
[23]
Tang Y,Liu T,Sun S,et al. Role and mechanism of growth differentiation factor 15 in chronic kidney disease [J]. J Inflamm Res,2024,17:2861-2871.
[24]
Ding C,Li J,Wei Y,et al. Associations of total homocysteine and kidney function with all-cause and cause-specific mortality in hypertensive patients: a mediation and joint analysis [J].Hypertens Res,2024,47(6):1500-1511.
[25]
Kobayashi S,Yamazaki H,Imamura T,et al. Implication of serum growth differentiation factor-15 level in patients with renal diseases [J]. Int Urol Nephrol,2023,55(11):2935-2941.
[26]
Lidgard B,Zelnickv L,Anderson AH,et al. Cardiac biomarkers and risk of atherosclerotic cardiovascular disease in patients with CKD [J]. Kidney360,2022,3(5):859-871.
[27]
Claus R,Berliner D,Bavendiek U,et al. Soluble neprilysin,NT-proBNP,and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients(SONGBIRD) [J]. Clin Res Cardiol,2020,109(8):1035-1047.
[28]
Kato ET,Morrow DA,Guo J,et al. Growth differentiation factor 15 and cardiovascular risk:individual patient meta-analysis[J].Eur Heart J,2023,44(4):293-300.
[29]
Eggers KM,Batra G,Lindahl B,et al. Temporal biomarker concentration patterns during the early course of acute coronary syndrome [J]. Clin Chem Lab Med,2024,62(6):1167-1176.
[30]
Alam ML,Katz R,Bellovich KA,et al. Soluble ST2 and galectin-3 and progression of CKD [J]. Kidney Int Rep,2018,4(1):103-111.
[31]
Hara A,Niwa M,Noguchi K,et al. Galectin-3 as a nextgeneration biomarker for detecting early stage of various diseases[J]. Biomolecules,2020,10(3):389.
[32]
Tummalapalli SL,Zelnick LR,Andersen AH,et al. Association of cardiac biomarkers with the Kansas city cardiomyopathy questionnaire in patients with chronic kidney disease without heart failure [J]. J Am Heart Assoc,2020,9(13): e014385.
[33]
Han X,Zhang S,Chen Z,et al. Cardiac biomarkers of heart failure in chronic kidney disease [J]. Clin Chim Acta,2020,510:298-310.
[34]
Liu S,Wu Q,Zhang S,et al. Serum galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients:a prospective cohort study [J]. BMC Nephrol,2022,23(1):5.
[35]
Bayes-Genis A,Zamora E,de Antonio M,et al. Soluble ST2 serum concentration and renal function in heart failure [J]. J Card Fail,2013,19(11):768-775.
[36]
Tuegel C,Katz R,Alam M,et al. GDF-15,galectin 3,soluble ST2,and risk of mortality and cardiovascular events in CKD[J]. Am J Kidney Dis,2018,72(4):519-528.
[37]
Filipska I,Winiarska A,Knysak M,et al. Contribution of gut microbiota-derived uremic toxins to the cardiovascular system mineralization [J]. Toxins (Basel),2021,13(4):274.
[38]
Lim YJ,Sidor NA,Tonial NC,et al. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease:mechanisms and therapeutic targets[J]. Toxins(Basel),2021,13(2):142.
[39]
Jing YJ,Ni JW,Ding FH,et al. p-Cresyl sulfate is associated with carotid arteriosclerosis in hemodialysis patients and promotes atherogenesis in ApoE-/-mice [J]. Kidney Int,2016,89(2):439-449.
[40]
Hsu CC,Lu YC,Chiu CA,et al. Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis [J]. Clin Invest Med,2013,36(1): E42-E49.
[41]
Li Q,Zhang S,Wu QJ,et al. Serum total indoxyl sulfate levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study [J]. BMC Nephrol,2022,23(1):231.
[42]
Nemet I,Saha PP,Gupta N,et al. A cardiovascular diseaselinked gut microbial metabolite acts via adrenergic receptors[J].Cell,2020,180(5):862-877.
[43]
Zhang Z,Cai B,Sun Y,et al. Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure [J]. Front Cardiovasc Med,2023,9:1076806.
[44]
Poesen R,Claes K,Evenepoel P,et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD [J]. J Am Soc Nephrol,2016,27(11):3479-3487.
[45]
Zhang Y,Wang Y,Ke B,et al. TMAO: how gut microbiota contributes to heart failure [J]. Transl Res,2021,228:109-125.
[46]
Gencer B,Li XS,Gurmu Y,et al. Gut microbiota-dependent trimethylamine N-oxide and cardiovascular outcomes in patients with prior myocardial infarction: a nested case control study from the PEGASUS-TIMI 54 trial [J]. J Am Heart Assoc,2020,9(10): e015331.
[47]
Shafi T,Powe NR,Meyer TW,et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients[J]. J Am Soc Nephrol,2017,28(1):321-331.
[48]
Stubbs JR,Stedman MR,Liu S,et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis [J]. Clin J Am Soc Nephrol,2019,14(2):261-267.
[49]
Genoni A,Christophersen CT,Lo J,et al. Long-term paleolithic diet is associated with lower resistant starch intake,different gut microbiota composition and increased serum TMAO concentrations[J]. Eur J Nutr,2019,59(5):1845-1858.
[50]
Yamada S,Nakano T. Role of chronic kidney disease (CKD)-mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD [J]. J Atheroscler Thromb,2023,30(8):835-850.
[51]
Kandarini Y,Mahadita GW,Herawati S,et al. High C-terminal fibroblast growth factor-23,intact parathyroid hormone,and interleukin-6 as determinants of valvular calcification in regular hemodialysis patients [J]. Int J Gen Med,2022,15:4227-4236.
[52]
Epstein M,Freundlich M. The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury [J]. Nephrol Dial Transplant,2022,37(2):211-221.
[53]
Yang K,Yang J,Bi X,et al. Serum Klotho,cardiovascular events,and mortality in nondiabetic chronic kidney disease [J].Cardiorenal Med,2020,10(3):175-187.
[54]
Silva AP,Mendes F,Carias E,et al. Plasmatic klotho and FGF23 levels as biomarkers of CKD-associated cardiac disease in type 2 diabetic patients [J]. Int J Mol Sci,2019,20(7):1536.
[1] 郝玥萦, 毛盈譞, 张羽, 汪佳旭, 韩林霖, 匡雯雯, 孟瑶, 杨秀华. 超声引导衰减参数成像评估肝脂肪变性及其对心血管疾病风险的预测价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 770-777.
[2] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[3] 杨桂清, 孟静静. 哺乳期亚临床乳腺炎的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 376-379.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[7] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[8] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[9] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[10] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[11] 刘柏隆, 周祥福. 女性尿失禁吊带手术并发症处理的经验分享[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 127-127.
[12] 嵇振岭, 陈杰, 唐健雄. 重视复杂腹壁疝手术并发症的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 601-606.
[13] 江志鹏, 钟克力, 陈双. 复杂腹壁疝手术后腹腔高压与腹腔间室综合征的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 612-615.
[14] 王学虎, 赵渝. 复杂腹壁疝手术中血管损伤并发症的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 616-619.
[15] 程柏凯, 杨光. 高胰岛素-正葡萄糖钳夹技术评估慢性肾脏病患者胰岛素抵抗的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 334-339.
阅读次数
全文


摘要